BioLineRx to Present at the 2012 Fifth Annual LD MICRO Conference in Los Angeles on December 5th
The Chief Executive Officer of BioLineRx, Dr.
Investors attending the conference that wish to meet with Dr. Savitsky or Mr. Serlin for a one-on-one meeting should notify their LD Micro contact.
About BioLineRx
BioLineRx is a publicly-traded biopharmaceutical development company.
BioLineRx is dedicated to building a portfolio of products for unmet
medical needs or with advantages over currently available therapies.
BioLineRx’s current portfolio consists of six clinical stage candidates:
BL-1020 for schizophrenia is currently undergoing a Phase II/III study;
BL-1040, for prevention of pathological cardiac remodeling following a
myocardial infarction, which has been out-licensed to
BioLineRx’s business model is based on acquiring molecules mainly from
biotechnological incubators and academic institutions. The Company
performs feasibility assessment studies and development through
pre-clinical and clinical stages, with partial funding from the Israeli
Government’s
For more information on BioLineRx, please visit www.biolinerx.com.
Source:
KCSA Strategic Communications
Garth Russell / Todd Fromer
1
212-896-1250 / 1 212-896-1250
grussell@kcsa.com
/ tfromer@kcsa.com
or
Tsipi
Haitovsky
Public Relations
+972-3-6240871
tsipih@netvision.net.il